---
figid: PMC9394232__MOL2-16-3034-g004
pmcid: PMC9394232
image_filename: MOL2-16-3034-g004.jpg
figure_link: /pmc/articles/PMC9394232/figure/mol213279-fig-0005/
number: Fig. 5
figure_title: ''
caption: The DDR, metabolic and immune‐related pathway landscape between gemcitabine‐resistant
  and ‐sensitive samples classified by 28‐GPS in TCGA. DDR, DNA damage response; 28‐GPS,
  28 gene pairs; TCGA, the cancer genome atlas; (A) Heatmap shows the ssGSEA enrichment
  scores of DDR, metabolism and immunity pathways. ssGSEA, single sample gene set
  enrichment analysis; R, resistant samples; S, sensitive samples. (B, C) The correlation
  network between DDR, metabolic and immune‐related pathways in resistant group (B)
  and sensitive group (C). [Colour figure can be viewed at wileyonlinelibrary.com]
article_title: Systematic exploration of the underlying mechanism of gemcitabine resistance
  in pancreatic adenocarcinoma.
citation: Kaidong Liu, et al. Mol Oncol. 2022 Aug;16(16):3034-3051.
year: '2022'

doi: 10.1002/1878-0261.13279
journal_title: Molecular Oncology
journal_nlm_ta: Mol Oncol
publisher_name: John Wiley and Sons Inc.

keywords:
- drug response signature
- gemcitabine
- immunity
- pancreatic ductal adenocarcinoma
- single cell

---
